Regeneron Pharmaceuticals, Inc. (REGN)
790.74
-5.60
(-0.70%)
USD |
NASDAQ |
Oct 16, 16:00
793.00
+2.26
(+0.29%)
After-Hours: 20:00
Regeneron Pharmaceuticals Cash from Investing (Quarterly) : -92.70M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -92.70M |
| March 31, 2026 | -428.90M |
| December 31, 2025 | 220.30M |
| September 30, 2025 | -402.90M |
| June 30, 2025 | -1.094B |
| March 31, 2025 | 647.50M |
| December 31, 2024 | 350.60M |
| September 30, 2024 | -574.40M |
| June 30, 2024 | -557.20M |
| March 31, 2024 | -1.687B |
| December 31, 2023 | -66.20M |
| September 30, 2023 | -496.30M |
| June 30, 2023 | -2.387B |
| March 31, 2023 | -235.70M |
| December 31, 2022 | -1.858B |
| September 30, 2022 | 192.30M |
| June 30, 2022 | -413.90M |
| March 31, 2022 | -1.705B |
| December 31, 2021 | -2.013B |
| September 30, 2021 | -2.439B |
| June 30, 2021 | 125.80M |
| March 31, 2021 | -1.059B |
| December 31, 2020 | -305.00M |
| September 30, 2020 | -775.80M |
| June 30, 2020 | 1.453B |
| Date | Value |
|---|---|
| March 31, 2020 | -443.20M |
| December 31, 2019 | -208.70M |
| September 30, 2019 | -207.00M |
| June 30, 2019 | -836.00M |
| March 31, 2019 | -776.10M |
| December 31, 2018 | -265.91M |
| September 30, 2018 | -286.71M |
| June 30, 2018 | -484.97M |
| March 31, 2018 | -425.41M |
| December 31, 2017 | -335.75M |
| September 30, 2017 | -358.88M |
| June 30, 2017 | -170.41M |
| March 31, 2017 | -140.14M |
| December 31, 2016 | -271.36M |
| September 30, 2016 | -405.85M |
| June 30, 2016 | -326.01M |
| March 31, 2016 | -43.68M |
| December 31, 2015 | -123.30M |
| September 30, 2015 | -283.17M |
| June 30, 2015 | -371.65M |
| March 31, 2015 | -129.48M |
| December 31, 2014 | 56.64M |
| September 30, 2014 | -123.07M |
| June 30, 2014 | -118.12M |
| March 31, 2014 | -236.23M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -569.00M |
| Biogen, Inc. | -3.839B |
| Incyte Corp. | -51.79M |
| Vertex Pharmaceuticals, Inc. | -45.80M |
| AbbVie, Inc. | -1.197B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 813.00M |
| Cash from Financing (Quarterly) | -1.225B |
| Free Cash Flow | 3.575B |
| Free Cash Flow Per Share (Quarterly) | 4.923 |
| Free Cash Flow to Equity (Quarterly) | 521.40M |
| Free Cash Flow to Firm (Quarterly) | 531.14M |
| Free Cash Flow Yield | 4.22% |